ERG and acute lymphoblastic leukemia: Notably, ChIP-seq data of lymphoid cancers, including BCP-ALL, showed that RUNX2, ERG, and ETS1 (Supplementary Material 4) bind to over 70% of the selected 108 loci (Fig. 4H).